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A B S T R A C T
All follow up protocols for patients with malignant melanoma (MM) are oriented to early detection of metastases. As
most of the relapses happened in regional lymph nodes, special attention is given to this region, using different diagnos-
tic tools. Sentinel lymph node biopsy (SLNB) is generally accepted method in determining status of lymph nodes in MM
patients, in their staging. This method provides valuable prognostic information, facilitates early therapeutical lympha-
denectomy and so provides good base for identification of those patients who are candidates for different adjuvant mo-
dalities of treatment. (In 2001 American Joint Committee on Cancer introduced new staging system for melanoma pa-
tients which presents good frame for prognosis and therapeutical approach. Inclusion of new criteria will allow better
and more individualized prognosis and treatment.) The most important predictor of SLNB outcome is thickness of tu-
mor according to Breslow, while there is no sufficient data to show correlation with other factors. We retrospectively stud-
ded 431 patients, out of which SLNB was performed on 188. Forty patients or 21.3% had positive lymph nodes. Our re-
sults showed strong correlation of tumor thickness and Clark level of invasion with SLNB outcome. Metastatic lymph
nodes were founded in all acral-lentiginous melanoma patients, followed by nodular melanoma – 55.6% and superficial
spreading melanoma – 14.1%. Results showed statistically significant predilection of positive SLNB in male patients
and no correlation of positive SLNB with histological type of tumor. On the contrary, it showed significant correlation
with development of metastases. Thus our results are similar to other comparable studies.
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Introduction
Malignant melanoma (MM) presents one of the most
malignant and unpredictable tumor which arises from
the melanocytic cells and primarily involves skin, even
though can arise in eye (conjunctiva and uvea), meninges
and mucosal surfaces. Melanomas take part of 90% of the
deaths associated with cutaneous tumors. The incidence
of melanoma is increasing worldwide4,5. The most impor-
tant etiological exogenous factor is exposure to ultravio-
let irradiation and endogenous is immune system impair-
ment, while role of other factors (toxic substances, medi-
cations, hormones) stays controversial. MM is tumor of
the middle age. In Croatia this tumor represents serious
public and health problem. According to data of National
Cancer Registry of Croatia it took 3% of total incidence of
all malignant tumors1 (incidence rate: 12.3 per 100 000
for females and 14.2 per 100,000 for males).
In follow up of these patients, which is based on early
detection of recidives, from special interest is early and
accurate diagnosis of primary tumor (staging), identifica-
tion of SLN, and of course separation and more close follow
up of those patients who are on a higher risk of develop-
ing metastasis. Prognosis given by staging is extremely
important, because it gives a good base for further strat-
egy on follow up and choice of different modalities of
treatment and of course facilitate early detection of dis-
tant metastasis in subclinical phase6.
Lymph node (LN) status is the most powerful prog-
nostic factor for early stage of MM. Therefore, lymph
node assessment is considered today as the main stay of
the staging process7. Only few years ago only objective
method to evaluate tumor involvement of the certain LN
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drainage area was elective Radical Lymph Node Dissec-
tion (RLND) and the patohistological examination. This
method provides high rate of complications and high per-
centage of patients underwent risk procedures without
any benefit.
Sentinel Lymph Node Biopsy (SLNB) is an alterna-
tive method which reliably allows detection of LN metas-
tasis in patients with primary MM, while at the same
time avoids surgical trauma with high complication rate
(20–30%)8.
But, approximately 80% of melanoma patients under-
going SLNB have negative sentinel lymph nodes (SLNs).
Today, we still have no predictor reliable enough to be
implemented in the clinical setting in order to reduce the
number of SNB procedures9. There is a continuous effort
to reduce this high portion of an unnecessary SNB, but
to keep satisfactory level of accuracy at the same time.
Many different clinicopathological variables were consid-
ered: the patient’s age, gender, the tumor’s type, Breslow
thickness, Clark level, ulceration, mitotic index, lympho-
cyte infiltration, regression, angiolymphatic invasion, mi-
crosatellitosis, and growth phase or even combination of
different variables8,9. Some studies showed that thick-
ness could be reliable independent prognostic factors for
SLN positivity10,11–12,13.
The main aim of our study was to examine correlation
of tumor thickness and outcome on SNB. On the same
group of patients we also tested correlation of gender,
type and level of tumor invasion with sentinel node sta-
tus. We were hoping that all of this will help us to iden-
tify group of higher risk patients and to find a way of re-
ducing number of unnecessary procedures at the same
time. Moreover, better predictivity in early stage of dis-
eases could significantly influence our interventions and
consequently have positive impact on the course of dis-
ease.
Patients and Methods
This retrospective study was performed based on data
from Croatian State Referral Centre for Malignant Mela-
noma, at University Hospital »Sestre milosrdnice«. For
analysis we used clinical records of 431 patients: 228 fe-
male and 197 male patients. They were all diagnosed and
followed from 2005 to 2007 (121 patients in 2005, 125 in
2006 and 185 in 2007). Out of this group 188 patients un-
derwent SNB at our institution.
There was only one inclusion criterion: equal or more
than 1.00 mm of Breslow thickness. From all of patients
included in analysis, who underwent SLNB in our insti-
tution 15 patients did not meet mentioned criteria (12 of
them with Breslow thickness from 0.75 to 1 mm). From
188 patients on whom SLNB was performed, 40 patients
(21.3%) had positive sentinel nodes. The four tables rep-
resent distribution of the main clinicopatological param-
eters: tumor’s histological subtype (Table 1), localization
of tumor (Table 2), tumor invasion by Clark level (Table
3) and Breslow thickness (Table 4).
Diagnosis of MM (histological subtype, Clarck and
Breslow level) was done based on the histopathological
examination of the surgically removed lesions. Tumor
thickness was determined according to criteria of Breslow
into four groups: (I: 0–0.75 mm; II: 0.76–1.5 mm; III:
1.5–4.00 mm and IV: >4.00 mm). Invasion of tumor is de-
termined by Clark criteria into five groups: (I: tumor
cells in epidermis only (melanoma in situ); II: tumor cells
extend from epidermis into (but do not fill) papillary
dermis); III: tumor cells extend from epidermis into and
fill papillary dermis; IV: tumor cells extend into reticular
dermis; V: tumor cells extend through the dermis into










Superficial spreading melanoma 127 61.4
Nodular melanoma 51 24.6
Lentigo maligna melanoma 19 9.2







Localization Number of patients Valid Percent
Head and neck 36 8.5
Trunk front side 58 13.6
Trunk back side 166 39.1
Head and shoulder 57 13.4
Leg and hip 88 20.7
Acral localization 11 2.6
Eye 2 0.5
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underlying subcutaneous fat. SN was identified by the
standard procedure of preoperative lymphoscintigraphy
with radioactive nanocolloid and intraoperative use of a
hand – held gamma probe. SNs were pathologically ana-
lyzed according to EORTC Melanoma Group protocol
(staining was standard: H&E, S100 and HMB-45). Cor-
relation of SLNB results and traditional melanoma prog-
nostic indicators were analyzed by SPSS 12.0, standard
statistical analytical program.
Results
Mean age of our patients was 53.55 yrs (SD=14.85),
ranging from 7 to 90 yrs of age. Mean Breslow thickness
was 2.15 mm (SD=2.15) in range between 0.11 to 14.00
mm. Our results showed slightly higher incidence of pos-
itive sentinel lymph nodes in male patients with statisti-
cally proven correlation of gender and SLNB outcome
(p<0.05). Rate of positive sentinel nodes increased with
higher tumor thickness, higher Breslow and Clark level.
As assumed, we also founded strong correlation of tumor
thickness and appearance of metastases. All correlations
were with p<0.05. Histological subtype of melanoma was
unable to predict SLNB outcome, but as a contrary in
correlation analysis we founded different malignant po-
tential of developing metastases by different type of tu-
mor (p<0.05). According to type of melanoma: all of our
patients with Acral Lentiginous Melanoma (ALM) devel-
oped metastases (valid 2; missing system 3; 100 valid per-
cent); in the group of patients with Nodular Melanoma
Malignum (NMM) 55.6% of patients developed meta-
stases (valid 27; missing system 24; 55.6 valid percent).
In Superficial Spreading Melanoma (SSM) group, 14.1%
developed metastases (valid 64; missing system 63; 14.1
valid percent). Nobody from Lentigo Maligna Melanoma
(LMM) group didn’t develop metastases (valid 4; missing
system 15; 100.0 valid percent). In the group of patients
with Breslow thickness I, there were no positive sentinel
nodes, and no detected metastases. In Breslow thickness
II group were 10.3% (valid percent) of positive lymph
nodes, and 21.6% (valid percent) of metastases. Breslow
thickness III group of our patients had positive nodes in
19.1% (valid percent), and 40.4% of metastatic develop-
ment. In Breslow thickness IV group 40.5% (valid per-
cent) had positive sentinel nodes and 69.0% (valid per-
cent) of them developed metastases. In separate analyzes
of the group of 34 patients with MM thickness equal or
less than 1 mm (partly met inclusion criteria), 4 patients
had positive sentinel lymph nodes.
Discussion and Conclusion
Our research showed similar results as other compa-
rable studies. As expected we founded correlation be-
tween thickness and invasion of tumor with incidence of
positive SLNs, as well as higher predilection of positive
sentinel nodes with male gender. Last we can explain
with worse prognosis of male melanoma patients14. It
seems from our and many other studies that thickness by
itself can be independent selector of those patients who
will undergo SLNB. We, as most of other melanoma cen-
ters are performing SLNB on all of the patients with
thickness of more than 1 mm. But, do we take too wide
safety margin? Or, do we risk too much? Most of the con-
troversies arise within the group of thin (less than 1
mm), thick melanomas (more than 4 mm), and from the
group of locally recurrent melanomas15. We also had few
exemptions from the „rule« not to do SLNB for MM of
thickness less than 1 mm. Most of them were very close
to 1 mm, or dissection was based on some other clinical
facts. The youngest patient on whom SLNB was per-
formed, although he did not meet criteria, was 10 yrs old
with 0.85 mm of tumor thickness. We learned that from
that group 4 of our patients had positive sentinel nodes
(all of them between 0.75 and 1 mm). We didn’t have any
positive sentinel nodes in Breslow I stage within our pa-
tients. Knowing that course of disease is worse with a
younger age, we could ask ourselves: do we need to ex-
clude some of our younger patients from the general rule,
especially if we face with aggressive type of tumor, and
tumor thickness is over 0.75 mm. On the other hand
from literature and our experience we know that there is
a huge number of „unnecessary« performed SLNB – neg-
ative results. We are aware of that, but there is still no al-
ternative. Finding a better way to reduce some of unnec-
essary performed SLNB, will lead us to obvious advan-
tage in terms of patient’s quality of life and financial sav-
ings. Further studies will give the answer. We hope that
implementation of non-invasive and cheaper methods for
preoperative staging and follow up will improve sensitiv-
ity and specificity of current diagnostic tools. In this re-
spect we are planning to prospectively study possibilities
and limits of ultra sound (US) and US guided biopsy16
alone or in combination with other methods.
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NA[A ISKUSTVA O DEBLJINI MELANOMA KAO PREDIKTORU ISHODA SENTINEL BIOPSIJE
S A @ E T A K
Svi protokoli pra}enja bolesnika oboljelih od malignog melanoma, orijentirani su ka ranoj detekciji metastaza. Obzi-
rom da se ve}ina relapsa zbiva u regionalnim limfnim ~vorovima, posebna pa`nja posve}ena je toj regiji, koriste}i razli-
~ite dijagnosti~ke alate. Sentinel biopsija limfnog ~vora (SLNB) je op}enito prihva}ena metoda u odre|ivanju statusa
limfnih ~vorova bolesnika, odnosno u postupku stupnjevanja bolesti. Ova metoda omogu}uje vrijednu prognosti~ku
informaciju, doprinose}i ranoj terapeutskoj limfadenektomiji i ujedno pru`a dobru osnovu za identifikciju onih bole-
snika koji su kandidati za razli~ite adjuvantne modalitete lije~enja. 2001. American Joint Committee on Cancer uveo je
novo stupnjevanje melanoma, koje predstavlja dobar okvir za prognozu i terapeutski pristup. Daljnje uklju~ivanje novih
kriterija omogu}it }e bolji i individualizirani tretman. Najva`niji prognosti~ki ~imbenik ishoda SLNB je debljina tu-
mora, prema Breslow-u. Retrospektivno smo prou~avali 431 bolesnika, od kojih je SLNB izvr{ena na 188. 40 bolesnika
ili 21,3% imalo je pozitivne limfne ~vorove. Na{i rezultati pokazali su ~vrstu korelaciju debljine tumora i stupnja inva-
zije po Clarku sa ishodom SLNB. Metastatski limfni ~vorovi prona|eni su kod svih bolesnika sa akro-lentiginoznim
melanomom, slijedi nodularni melanom sa 55,6% bolesnika kod kojih su prona|eni metastatski limfni ~vorovi, te povr-
{insko-{ire}i tip melanoma sa 14,1%. Rezultati su pokazali statisti~ki zna~ajnu predilekciju pozitivnih limfnih ~vorova
kod mu{kih bolesnika. Povezanost pozitivnih ~vorova i histolo{kog tipa tumora nije dokazana, iako je tip tumora po-
kazao korelaciju sa razvojem metastaza. Na{i rezultati, tako su sli~ni onima u drugim komparativnim studijama.
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